NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) (OTCBB:LEVP.OB) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s filing of its Biologics License Application (BLA) for Cinryze™ (C1 inhibitor) for the acute treatment of hereditary angioedema (HAE). In addition, the FDA has designated the submission for priority review, which targets an FDA action by January 30, 2008. Lev submitted the BLA on July 31, 2007. Priority review status is granted by the FDA to products that, if approved, would be a significant improvement over existing therapies.
